Cara Therapeutics, Inc. (CARA) financial statements (2020 and earlier)

Company profile

Business Address 4 STAMFORD PLAZA
STAMFORD, CT 06902
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:249183935810753
Cash and cash equivalents35159121553
Short-term investments158146834692 
Other undisclosed cash, cash equivalents, and short-term investments5621  (0) 
Restricted cash and investments 0 1  
Receivables221100
Prepaid expense952220
Other undisclosed current assets(56)(21)000 
Total current assets:203168956110953
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment111212
Long-term investments and receivables5621    
Long-term investments5621    
Restricted cash and investments001111
Total noncurrent assets:60232223
TOTAL ASSETS:264191976411156
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:211491252
Accounts payable1044521
Accrued liabilities110110
Employee-related liabilities322211
Other undisclosed accounts payable and accrued liabilities862421
Deferred revenue27
Debt1     
Deferred revenue and credits   1
Contract with customer, liability27
Total current liabilities:484091253
Noncurrent Liabilities
Long-term debt and lease obligation4     
Operating lease, liability4
Liabilities, other than long-term debt 172213
Deferred revenue and credits2213
Accounts payable and accrued liabilities     0
Contract with customer, liability15
Deferred rent credit 2
Total noncurrent liabilities:4172213
Total liabilities:5257101367
Stockholders' equity
Stockholders' equity attributable to parent212134875110552
Common stock000000
Additional paid in capital584428307213210132
Accumulated other comprehensive income (loss)0(0)(0)0(0) 
Accumulated deficit(372)(294)(220)(162)(105)(80)
Total stockholders' equity:212134875110552
TOTAL LIABILITIES AND EQUITY:264191976411158

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:21131043
Operating expenses(125)(91)(60)(58)(29)(21)
Operating loss:(104)(77)(59)(58)(25)(18)
Nonoperating income
(Other Nonoperating income)
43110 
Loss from continuing operations before equity method investments, income taxes:(99)(74)(58)(58)(25)(18)
Other undisclosed income from continuing operations before income taxes     0
Loss from continuing operations before income taxes:(99)(74)(58)(58)(25)(18)
Income tax benefit100000
Net loss available to common stockholders, diluted:(98)(74)(58)(57)(25)(18)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(98)(74)(58)(57)(25)(18)
Other comprehensive income (loss)0(0)(0)0(0) 
Comprehensive loss, net of tax, attributable to parent:(98)(74)(58)(57)(25)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: